Status:
COMPLETED
A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Quintiles, Inc.
Conditions:
Rheumatoid Arthritis
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
This study is being performed to investigate the potential for AZD5672 to affect the electrical conduction pathways in the heart. AZD5672 will be compared against a drug (moxifloxacin - a licensed ant...
Eligibility Criteria
Inclusion
- Body Mass Index (BMI) between 18 and 30 kg/m2 and a minimum weight of 50kg.
- Non-smoker
Exclusion
- Marked QTc prolongation at baseline e.g. repeated demonstration of QTc interval \>450ms or marked shortening of QTcF \<350ms
- Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with the interpretation of the QTc Interval changes
- Use of concomitant medications that prolong QT/QTc interval
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2009
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00887770
Start Date
April 1 2009
End Date
July 1 2009
Last Update
July 16 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
London, United Kingdom